19:54 , Nov 2, 2018 |  BC Week In Review  |  Clinical News

Genentech's faricimab improves BCVA in Phase II for wet AMD

Genentech Inc. reported data from the Phase II STAIRWAY trial to treat wet age-related macular degeneration (AMD) showing that faricimab (RG7716) dosed every 12 or 16 weeks led to sustained improvements in visual outcomes that...
17:21 , Apr 13, 2018 |  BC Week In Review  |  Financial News

Abpro planning $69M NASDAQ listing

Antibody company Abpro Corp. (Woburn, Mass.) filed on April 12 to raise up to $69 million in an IPO on NASDAQ underwritten by UBS, Wells Fargo, Nomura and Oppenheimer. Abpro's two lead programs, ABP-100 and...
17:20 , Apr 12, 2018 |  BC Extra  |  Financial News

Abpro planning $69M NASDAQ listing

Antibody company Abpro Corp. (Woburn, Mass.) filed to raise up to $69 million in an IPO on NASDAQ underwritten by UBS, Wells Fargo, Nomura and Oppenheimer. Abpro's two lead programs, ABP-100 and ABP-201, are designed...
20:35 , Feb 23, 2018 |  BC Week In Review  |  Clinical News

Roche reports Phase II data for bispecific DME candidate

Roche (SIX:ROG; OTCQX:RHHBY) reported data from the Phase II BOULEVARD trial to treat diabetic macular edema (DME) showing that once-monthly 6 mg intravitreal RG7716 for 20 weeks met the primary endpoint of improving mean best...
04:08 , Dec 15, 2017 |  BC Week In Review  |  Clinical News

FDA accepts Regeneron's sBLA for 12-week Eylea dosing

Regeneron Pharmaceuticals Inc. (NASDAQ:REGN) said FDA accepted an sBLA for a quarterly dosing schedule of Eylea aflibercept to treat wet age-related macular degeneration (AMD). Its PDUFA date is Aug. 11, 2018. The drug is already...
21:42 , Dec 1, 2017 |  BC Week In Review  |  Clinical News

Regeneron to discontinue nesvacumab/Eylea combo

Regeneron Pharmaceuticals Inc. (NASDAQ:REGN) said it will discontinue development of a fixed combination therapy comprising nesvacumab (REGN910) plus Eylea aflibercept to treat diabetic macular edema (DME) and wet age-related macular degeneration (AMD) after the combination...
22:10 , Nov 27, 2017 |  BC Extra  |  Clinical News

Regeneron discontinues Eylea/nesvacumab combo

Regeneron Pharmaceuticals Inc. (NASDAQ:REGN) said it will discontinue development of a fixed combination therapy comprising nesvacumab (REGN910) plus Eylea aflibercept to treat diabetic macular edema (DME) and wet age-related macular degeneration (AMD) after the combination...
23:10 , Oct 6, 2017 |  BioCentury  |  Finance

Coasting on catalysts

While buysiders do not expect any sector-moving milestones in the wake of a catalyst-heavy third quarter, they will have at least 21 Phase III milestones and 23 PDUFA dates on their radar. But the biggest...
19:09 , Jan 18, 2017 |  BC Innovations  |  Distillery Techniques

Biomarkers

TECHNOLOGY: Plasma markers Serum ANG2 levels could help predict responses to anti- CTLA4 or anti- PD-1 mAbs in melanoma patients. In 134 melanoma patients treated with the anti-CTLA4 mAb Yervoy ipilimumab, Yervoy plus a biosimilar...
21:49 , Dec 2, 2016 |  BC Week In Review  |  Company News

Abpro, AstraZeneca deal

The MedImmune LLC unit of AstraZeneca and Abpro partnered to develop MedImmune's preclinical bispecific antibody that targets angiopoietin 2 ( ANG2 ; ANGPT2) and VEGF for multiple undisclosed indications. Abpro will use its DiversImmune platform...